Supplementary Figure S6 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy

Katsushige Kawase; Shusuke Kawashima; Tatsuya Nishi; Takashi Inozume; Takao Morinaga; Masahito Kawazu; Toyoyuki Hanazawa; Yosuke Togashi

doi:10.1158/2326-6066.30255046

October 1, 2025

Supplementary Figure S6 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy

View Full Paper

Ask AI

Bookmark

Share

Key Points

Dyrk1a regulates CD155 expression, which impacts cancer immunotherapy response.
Findings show that modulation of CD155 leads to significant effects in EMT6 and B16F10 cells.
Analysis focuses on the PI3K/Akt signaling pathway and its role in CD155 regulation.
Understanding CD155 dynamics is crucial for improving immunotherapy outcomes.

Implication

Observational analysis reveals that Dyrk1a influences CD155 expression in EMT6 and B16F10 cells, suggesting a role in cancer immunotherapy resistance.

Abstract

Additional data on the involvement of Dyrk1a in CD155 expression in EMT6 and B16F10 cells

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kawase et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a21ae2 https://doi.org/10.1158/2326-6066.30255046

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S6 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S6 from PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading